BR112024002195A2 - USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMAL - Google Patents
USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMALInfo
- Publication number
- BR112024002195A2 BR112024002195A2 BR112024002195A BR112024002195A BR112024002195A2 BR 112024002195 A2 BR112024002195 A2 BR 112024002195A2 BR 112024002195 A BR112024002195 A BR 112024002195A BR 112024002195 A BR112024002195 A BR 112024002195A BR 112024002195 A2 BR112024002195 A2 BR 112024002195A2
- Authority
- BR
- Brazil
- Prior art keywords
- antiviral
- animal
- viral disease
- nucleoside
- induce
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title abstract 5
- 241001465754 Metazoa Species 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 150000003833 nucleoside derivatives Chemical class 0.000 title abstract 3
- 230000005860 defense response to virus Effects 0.000 title abstract 2
- 241000282324 Felis Species 0.000 abstract 2
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282465 Canis Species 0.000 abstract 1
- 208000000655 Distemper Diseases 0.000 abstract 1
- 241000283073 Equus caballus Species 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 abstract 1
- 206010051497 Rhinotracheitis Diseases 0.000 abstract 1
- 208000014058 canine distemper Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000005098 feline infectious peritonitis Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21190172 | 2021-08-06 | ||
| EP22185716 | 2022-07-19 | ||
| PCT/EP2022/072074 WO2023012329A1 (en) | 2021-08-06 | 2022-08-05 | Method of treating veterinary viral diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112024002195A2 true BR112024002195A2 (pt) | 2024-04-30 |
Family
ID=83151800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112024002195A BR112024002195A2 (pt) | 2021-08-06 | 2022-08-05 | USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMAL |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240342204A1 (https=) |
| EP (1) | EP4380578A1 (https=) |
| JP (1) | JP2024528237A (https=) |
| AU (1) | AU2022323465A1 (https=) |
| BR (1) | BR112024002195A2 (https=) |
| CA (1) | CA3226836A1 (https=) |
| MX (1) | MX2024001645A (https=) |
| WO (1) | WO2023012329A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5030587B2 (ja) | 2003-06-26 | 2012-09-19 | バイオトロン・リミテッド | 抗ウイルスアシルグアニジン化合物および方法 |
| NZ615939A (en) | 2011-05-10 | 2015-04-24 | Aratana Therapeutics Nv | Compounds for use in the treatment of feline retroviral infections |
| GB201203180D0 (en) | 2012-02-24 | 2012-04-11 | Okapi Sciences Nv | Compounds for treating parvovirus infection |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| KR20200140274A (ko) | 2018-03-07 | 2020-12-15 | 에모리 유니버시티 | 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도 |
-
2022
- 2022-08-05 CA CA3226836A patent/CA3226836A1/en active Pending
- 2022-08-05 JP JP2024506795A patent/JP2024528237A/ja active Pending
- 2022-08-05 US US18/294,592 patent/US20240342204A1/en active Pending
- 2022-08-05 WO PCT/EP2022/072074 patent/WO2023012329A1/en not_active Ceased
- 2022-08-05 AU AU2022323465A patent/AU2022323465A1/en active Pending
- 2022-08-05 BR BR112024002195A patent/BR112024002195A2/pt unknown
- 2022-08-05 EP EP22762011.9A patent/EP4380578A1/en active Pending
- 2022-08-05 MX MX2024001645A patent/MX2024001645A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3226836A1 (en) | 2023-02-09 |
| WO2023012329A1 (en) | 2023-02-09 |
| JP2024528237A (ja) | 2024-07-26 |
| US20240342204A1 (en) | 2024-10-17 |
| AU2022323465A1 (en) | 2024-02-01 |
| MX2024001645A (es) | 2024-02-27 |
| EP4380578A1 (en) | 2024-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112024002195A2 (pt) | USOS DE UM NUCLEOSÍDEO ANTIVIRAL ß-d-N(4)-HIDROXICITIDINA PARA PREVENIR OU TRATAR UMA DOENÇA VIRAL OU PARA INDUZIR UMA RESPOSTA ANTIVIRAL EM UM ANIMAL | |
| BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
| MX2022010659A (es) | Compuestos altamente activos contra la enfermedad por coronavirus de 2019 (covid-19). | |
| BR112022017243A2 (pt) | Lactoferrina para uso oral com ação antiviral | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| BR9914097A (pt) | Composto, uso do mesmo, composição farmacêutica e método de profilaxia ou tratamento de uma infecção viral e processo para preparação do composto | |
| JP2007508234A5 (https=) | ||
| DE122007000062I1 (de) | Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus | |
| HRP20050192B1 (hr) | Cjepivo za infekcije dišnog i spolnog sustava kod goveda | |
| RU2005128790A (ru) | Модифицированные живые вакцины, содержащие вирус бычьего герпеса типа 1 (bhv-1(ibr)) и/или вирус бычьей вирусной диареи (bvdv), для беременных и вскармливаемых особей скота | |
| JP2023535204A5 (https=) | ||
| BR112023001129A2 (pt) | Pró-fármacos antivirais, formulações farmacêuticas e métodos | |
| BR112022012255A2 (pt) | Formulações injetáveis de ação prolongada de sais de pamoato de cetamina | |
| KR870006900A (ko) | 항바이러스 조성물 | |
| JP2024528237A5 (https=) | ||
| WO2008036747A2 (en) | Composition and method for immunomodulation | |
| KR910000734A (ko) | 네플라노신 유도체 | |
| MX2023004516A (es) | Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion. | |
| JP2010528053A (ja) | インフルエンザ感染症を治療するための物質および方法 | |
| MX9301922A (es) | Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv). | |
| BR112022019357A2 (pt) | Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c | |
| ES2296820T3 (es) | Nuevos usos de agonistas 5-ht1a y de inhibidores de reabsorcion de serotina combinadas. | |
| BR112023003987A2 (pt) | Composição farmacêutica compreendendo hidroxicloroquina e seus usos | |
| RU2024105614A (ru) | Способ лечения вирусных ветеринарных заболеваний | |
| WO2001045727A2 (en) | Stabilized veterinary compositions comprising more than one antiviral agent |